Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Nektar Therapeutics revenue
Nektar Therapeutics's revenue is $98.4 million.
What is Nektar Therapeutics's revenue?
- Nektar Therapeutics's revenue growth from 1999 to 2024 is 137.99%.
- Nektar Therapeutics has 718 employees, and the revenue per employee ratio is $137,084.
- Nektar Therapeutics's peak quarterly revenue was $1.1B in 2018(q2).
- Nektar Therapeutics peak revenue was $1.2B in 2018.
- Nektar Therapeutics annual revenue for 2023 was 90.1M, -2.1% growth from 2022.
- Nektar Therapeutics annual revenue for 2024 was 98.4M, 9.22% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Nektar Therapeutics historical revenue
Nektar Therapeutics's peak revenue was $1.2B in 2018. The peak quarterly revenue was $1.1B in 2018(q2).
Nektar Therapeutics's revenue increased from $41.4m in 1999 to $98.4M currently. That's a 137.99% change in annual revenue.
Nektar Therapeutics annual revenue
Nektar Therapeutics annual revenue over time
| Fiscal year / year | Nektar Therapeutics revenue |
|---|---|
| 2009 | $71.9M |
| 2010 | $159.0M |
| 2011 | $71.5M |
| 2012 | $81.2M |
| 2013 | $148.9M |
| 2014 | $200.7M |
| 2015 | $230.8M |
| 2016 | $165.4M |
| 2017 | $307.7M |
| 2018 | $1.2B |
| 2019 | $114.6M |
| 2020 | $152.9M |
| 2021 | $101.9M |
| 2022 | $92.1M |
| 2023 | $90.1M |
| 2024 | $98.4M |
How accurately did Nektar Therapeutics' revenue projections match actual performance?
Nektar Therapeutics annual growth
Nektar Therapeutics saw the greatest revenue growth in 2018, when revenue increased by 287.81%.
Nektar Therapeutics had the lowest revenue growth in 2019, when revenue changed by -90.4%.
Nektar Therapeutics annual growth rate over time
| Year | Nektar Therapeutics growth |
|---|---|
| 2009 | -20%↓ |
| 2010 | 121%↑ |
| 2011 | -55%↓ |
| 2012 | 14%↑ |
| 2013 | 83%↑ |
| 2014 | 35%↑ |
| 2015 | 15%↑ |
| 2016 | -28%↓ |
| 2017 | 86%↑ |
| 2018 | 288%↑ |
| 2019 | -90%↓ |
| 2020 | 33%↑ |
| 2021 | -33%↓ |
| 2022 | -10%↓ |
| 2023 | -2%↓ |
| 2024 | 9%↑ |
Nektar Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Nektar Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | $9.7M | $13.0M | $10.2M | $39.0M |
| 2010 | $33.2M | $42.6M | $37.9M | $45.3M |
| 2011 | $11.3M | $17.3M | $27.1M | $15.8M |
| 2012 | $17.9M | $23.7M | $18.4M | $21.1M |
| 2013 | $23.0M | $33.9M | $60.9M | $31.1M |
| 2014 | $19.8M | $28.5M | $132.9M | $19.6M |
| 2015 | $108.8M | $22.7M | $60.0M | $39.4M |
| 2016 | $58.9M | $32.8M | $36.3M | $37.5M |
| 2017 | $24.7M | $34.6M | $152.9M | $95.5M |
| 2018 | $38.0M | $1.1B | $27.8M | $39.8M |
| 2019 | $28.2M | $23.3M | $29.2M | $33.9M |
| 2020 | $50.6M | $48.8M | $30.0M | $23.5M |
| 2021 | $23.6M | $28.3M | $24.9M | $25.0M |
| 2022 | $24.8M | $21.6M | $23.6M | $22.0M |
| 2023 | $21.6M | $20.5M | $24.1M | $23.9M |
| 2024 | $21.6M | $23.5M | $24.1M | $29.2M |
Nektar Therapeutics jobs nearby
Do you work at Nektar Therapeutics?
Is Nektar Therapeutics transparent about its revenue structure?
Nektar Therapeutics financial information
| CEO | Howard W. Robin |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 718 |
| Date Founded | 1990 |
| Headquarters | San Francisco, California |
| Number of Locations | 2 |
| Revenue | $98.4M |
| Net Income | -$368,198,000 |
| Gross Proft | $67.7M (2024) |
| EBITDA | ($180.0M) (2005) |
| PE Ratio | -61.46 |
| Tax Rate | 0.0% |
| Market Capitalization | $7.3B |
| Total Assets | $710,600,000 |
| Ticker | NKTR |
Nektar Therapeutics jobs you might like
Nektar Therapeutics financing
Nektar Therapeutics received early financing of $125.0M on 2012-07-01.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Debt | $125M | 07/2012 |
| Post Ipo Equity | $25M | 08/2013 |
| Post Ipo Equity | $20M | 06/2016 |
| Post Ipo Equity | $850.0M | 04/2018 |
| Post Ipo Equity | $150M | 02/2021 |
Nektar Therapeutics investors
| Investors | Security type |
|---|---|
| Deerfield | Post Ipo Debt |
| ASTRAZENECA PLC | Post Ipo Equity |
| SFJ Pharmaceuticals Inc | Post Ipo Equity |
Nektar Therapeutics competitors
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Amgen | $93,349 | $33.4B | 22,000 | 697 |
| Merck | $90,328 | $64.2B | 74,000 | 1,555 |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 2,041 |
| Hospira | $64,435 | $4.5B | 19,000 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Regeneron | $85,589 | $14.2B | 9,123 | 381 |
| Aerogen | $64,962 | $61.0M | 74 | 17 |
| Novartis | $112,479 | $51.7B | 110,000 | 386 |
| Nostrum Laboratories | $77,111 | $15.0M | 148 | - |
| DURECT | $76,438 | $2.0M | 88 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Nektar Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Nektar Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Nektar Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Nektar Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Nektar Therapeutics. The data presented on this page does not represent the view of Nektar Therapeutics and its employees or that of Zippia.
Nektar Therapeutics may also be known as or be related to Inhale Therapeutic Systems, Inc., NEKTAR THERAPEUTICS, Nektar, Nektar Therapeutics and Nektar Therapeutics Inc.